Study To Assess The Efficacy And Safety Of The Medical Device Iracross Versus Iraline Administered Intra-Articular To Patients With Knee Osteoarthritis

Inclusion Criteria: 1. Aged between 40 and 80 years 2. Symptomatic knee osteoarthritis as defined by the American College of Rheumatology (ACR) criteria; (for subjects with OA at both knees, the most painful one will be included in the study only, respecting KL grade II or III); 3. Ambulant without assistance; 4. Kellgren-Lawrence grade II or III on X-ray performed at maximum 6 months before screening; 5. VAS knee pain ≥40 at screening and 30 days before; 6. At least 30 days before screening oral/parenteral corticosteroid or NSAIDs (10 mg prednisone) administration. 7. Signed Informed consent Exclusion Criteria: 1. Unstable knee; 2. Varus or valgus ≥ 15 degrees; 3. Active malignancy; 4. Knee trauma or lose body parts 1 year before screening; 5. Rheumatoid Arthritis, avascular necrosis, fibromyalgia; 6. Use of potent analgesics 15 days (different from ≤ 10 mg prednisone); 7. Intra-articular HA or corticosteroid injection within 6 months before screening; 8. Arthroscopic or knee open surgery within 12 months before screening; 9. Body Mass Index (BMI) ≥ 40 kg/m2; 10. Active infection around the injection site; 11. Use of anticoagulants or history of thrombocytopenia; 12. Concomitant use of disease-modifying antirheumatic drugs (DMARDs), anaesthetics; 13. Known sensitivity to HA or DVS; 14. Pregnancy, breast feeding.